Consumer Reports Found Label Inaccuracies in Multivitamins. Lab Testing Shows Why It Keeps Happening.

A Consumer Reports investigation published earlier this year flagged a number of popular multivitamin products for failing to deliver what their labels promise. Some products contained less than 50% of their stated vitamin D. Others showed iron levels that varied by more than 30% from the label claim. The findings made headlines — but for anyone who runs potency testing day in and day out, none of it was surprising.

This isn’t a new problem. It’s a structural one. And it won’t get fixed until more manufacturers treat third-party lab verification as a non-negotiable part of their process, not an optional line item in the QC budget.

Why Multivitamin Potency Varies More Than Most People Expect

The US dietary supplement market generated roughly $60 billion in retail sales in 2024. A substantial portion of that is multivitamins — the most purchased supplement category in the country. With that kind of volume, you’d expect tight manufacturing controls and rigorous testing. The reality is messier.

Under 21 CFR Part 111, dietary supplement manufacturers are required to verify the identity, purity, strength, and composition of their products. The regulation has been in force since 2007. But the FDA doesn’t pre-approve supplements before they’re sold. There’s no pre-market review process like you’d see with pharmaceuticals. The burden is on the manufacturer to ensure their product meets label claims — and the FDA acts after the fact, typically through warning letters or recalls triggered by adverse event reports or third-party findings.

What this means in practice: a manufacturer can put “1,000 IU Vitamin D3” on a label, conduct minimal internal testing, and ship product without any independent verification. If their raw material supplier sent them material at 85% of stated potency, or if their blending process created hot spots, the consumer is the last to know.

The chemistry compounds the problem. Fat-soluble vitamins — A, D, E, and K — are sensitive to oxidation, heat, and moisture. Vitamin D3 in particular degrades meaningfully at elevated temperatures during tableting or encapsulation. A manufacturer who doesn’t account for this with appropriate overages and well-designed stability testing will see potency drop below label claim before the product even leaves the warehouse.

Water-soluble vitamins have their own headaches. Vitamin C and vitamin B12 are chemically incompatible in the same tablet matrix at close proximity — ascorbic acid accelerates the oxidative degradation of both cyanocobalamin and methylcobalamin. Manufacturers who co-formulate them without barrier coating or physical separation often find B12 potency cratering in finished product, even when the raw materials tested in spec at intake.

The Testing Gaps That Keep Showing Up

ConsumerLab, which has been independently testing dietary supplements since 1999, has documented over the years that roughly 20–30% of products they assess fail to meet label claims or have other quality issues. Their findings aren’t outliers — they’re consistent with what contract testing labs see when manufacturers submit finished product for third-party verification.

The specific failures tend to cluster in predictable places.

Vitamin D is the most common potency outlier. Because it’s assayed in IU at microgram-level concentrations, small homogeneity issues in the blend translate to large percentage deviations. We’ve seen finished-product lots where individual tablets from the same production run vary by ±35% in D3 content. That’s a blending problem, not a raw material problem — and it’s exactly the kind of variance that in-process blend uniformity testing is supposed to catch before a batch ships.

Folate has gotten more complicated since the industry shifted from folic acid to 5-methyltetrahydrofolate (5-MTHF). Methylfolate is more bioavailable, but it’s also less stable. Products listing 400 mcg of methylfolate in non-airtight packaging can lose 15–20% of potency within 6 months at ambient conditions. ICH Q1A(R2) stability guidelines provide the framework for establishing accurate shelf-life claims, but many supplement manufacturers don’t run formal ICH-compliant stability studies — which means their expiration dates are educated guesses at best.

Iodine is routinely undertested and, frankly, underappreciated as a problem ingredient. Potassium iodide, the most common iodine source in multivitamin formulas, is highly volatile in the presence of moisture and ascorbic acid. In humid climates or improperly stored product, iodine can volatilize to the point where a tablet claiming 150 mcg delivers fewer than 50 mcg by the time it reaches the consumer. That’s a more than 60% potency loss — enough to matter clinically for someone relying on that product for thyroid support.

What 21 CFR Part 111 Actually Requires — and Where Manufacturers Fall Short

The cGMP regulation for dietary supplements (21 CFR Part 111) is more detailed than a lot of manufacturers realize. It requires component testing on all incoming raw materials, blend uniformity testing during production, finished-product testing against label specifications before release, and retention of reserve samples from each lot for at least 1 year beyond the product’s shelf life. These aren’t suggestions. They’re regulatory minimums.

The gaps we see most often aren’t in manufacturers who outright ignore 21 CFR Part 111. Most mid-size and large supplement companies have documented cGMP procedures. The gap is in the rigor of execution. Internal labs — especially those under cost or schedule pressure — have a documented tendency toward confirmation bias. If the in-house HPLC method says the product passed, the batch ships. The method itself may not be validated to the same standard that an ISO 17025-accredited external lab would apply, and the analysts running it may not have the independence to escalate an anomalous result when a ship date is looming.

That’s not a knock on internal QC teams, many of whom are technically excellent. It’s a structural observation: when the lab doing the testing reports to the same business unit trying to hit a production target, analytical independence is compromised. Third-party testing — run by an accredited lab with no financial stake in the outcome — removes that conflict by design.

It’s also increasingly expected by retail partners. Major retailers have tightened their supplier qualification requirements meaningfully in recent years. Third-party certificates of analysis from ISO 17025-accredited labs are becoming a baseline expectation for shelf placement, not a differentiator.

What Brands and Consumers Should Actually Do

For consumers, the most direct protection is to look for products carrying a third-party verification seal: USP Verified, NSF International Certified, or a ConsumerLab approval mark. These programs require independent testing of finished product lots and conduct ongoing surveillance testing to ensure consistency over time. They’re not a guarantee of perfection, but they represent a meaningful quality floor that unverified products don’t meet.

If a product doesn’t carry one of those seals, look for a manufacturer that publishes third-party certificates of analysis on their website, indexed to specific production lots. Any brand that won’t share that documentation on request should give you serious pause.

For brands and contract manufacturers, the Consumer Reports investigation — and the steady accumulation of ConsumerLab failures — should be a clear signal about the risk of relying exclusively on internal testing. A finished-product potency panel from a qualified external lab runs a few hundred dollars per sample. That’s a trivial cost relative to the exposure from a product recall, an FDA warning letter, or the reputational damage of appearing in a negative national investigation.

At Qalitex, we run finished-product potency panels for vitamins A, B-complex, C, D, E, and K using USP and AOAC-validated HPLC methods, with ICP-MS for mineral quantification including iodine, zinc, selenium, and calcium. Our methods are accredited under ISO 17025, which means the analytical process has been independently assessed for technical competence — not just that the procedures exist on paper, but that we’ve demonstrated we can execute them accurately and reproducibly across analysts, instruments, and time.

The methodology choice matters more than most brands realize. A lab that quantifies vitamin D by UV spectrophotometry instead of HPLC will deliver less specific results, because UV methods can’t distinguish D3 from other UV-absorbing compounds in a complex matrix. Knowing to ask that question when selecting a testing partner is the kind of thing that separates a well-designed QC program from one that’s mostly paperwork.

For EU market entry and European regulatory compliance, Care Europe provides expert consulting from Paris.

For raw material and ingredient-level verification, Ayah Labs specializes in contract testing and supplier qualification.

The Standard Keeps Climbing

The Consumer Reports investigation won’t prompt the FDA to implement pre-market approval for dietary supplements. That’s not how the regulatory framework is structured, and it’s not a realistic near-term development. What investigations like this consistently do is sharpen consumer attention, raise the floor for what sophisticated retail buyers will accept, and put every brand that’s been coasting on lax internal testing on notice.

Brands that treat third-party potency testing as a checkbox will keep getting caught. Brands that build independent verification into every production cycle, run stability studies under ICH-aligned protocols, and can produce a full batch record and CoA within 24 hours of a retailer or regulator asking for it occupy a fundamentally different risk profile — and a different market position — over the next five years.

The data isn’t complicated. Somewhere between one in four and one in five supplements on US shelves has a meaningful discrepancy between the label and what analytical chemistry actually finds. For multivitamins specifically, where millions of consumers are making daily decisions about nutritional adequacy, that failure rate is unacceptable. The manufacturers who internalize that first are the ones who will still be on shelves when the regulatory environment eventually tightens — and the ones who won’t be in the next Consumer Reports headline.